<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Approach</title>
	<atom:link href="http://www.tapanray.in/tag/approach/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Effective Change Management &#8211; The Magic Wand For Business Success And Sustainability</title>
		<link>http://www.tapanray.in/effective-change-management-the-magic-wand-for-business-success-and-sustainability/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=effective-change-management-the-magic-wand-for-business-success-and-sustainability</link>
		<comments>http://www.tapanray.in/effective-change-management-the-magic-wand-for-business-success-and-sustainability/#comments</comments>
		<pubDate>Mon, 27 Feb 2023 00:00:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ADP]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[changes]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[magic wand]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10748</guid>
		<description><![CDATA[Change – just as it’s an integral part of our life, so is for any business, including pharmaceutical or healthcare. Interestingly, the phase of transition of such changes isn’t always slow and gradual. In many cases, especially for business, or &#8230; <a href="http://www.tapanray.in/effective-change-management-the-magic-wand-for-business-success-and-sustainability/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/effective-change-management-the-magic-wand-for-business-success-and-sustainability/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Covid Propels Healthcare Into A Virtual World: A New Growth Driver For Pharma?</title>
		<link>http://www.tapanray.in/covid-propels-healthcare-into-a-virtual-world-a-new-growth-driver-for-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=covid-propels-healthcare-into-a-virtual-world-a-new-growth-driver-for-pharma</link>
		<comments>http://www.tapanray.in/covid-propels-healthcare-into-a-virtual-world-a-new-growth-driver-for-pharma/#comments</comments>
		<pubDate>Mon, 19 Oct 2020 00:00:43 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Collaborative]]></category>
		<category><![CDATA[consultation]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[driver]]></category>
		<category><![CDATA[e-commerce]]></category>
		<category><![CDATA[e-health]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[propels]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[remote]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[Telehealth]]></category>
		<category><![CDATA[telemedicine]]></category>
		<category><![CDATA[virtual]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10299</guid>
		<description><![CDATA[Amid ongoing Covid pandemic, most discussions on pharma specific ‘digitalization’ initiatives continue to predominantly hover around its traditional business growth drivers. In fact, even before the Covid time, it was no different, in a smaller scale and with a lesser &#8230; <a href="http://www.tapanray.in/covid-propels-healthcare-into-a-virtual-world-a-new-growth-driver-for-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/covid-propels-healthcare-into-a-virtual-world-a-new-growth-driver-for-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Time For Predictive Rather Than Reactive Pharma Strategy</title>
		<link>http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=time-for-predictive-rather-than-reactive-pharma-strategy</link>
		<comments>http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/#comments</comments>
		<pubDate>Mon, 15 Jun 2020 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[first in class]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[me-too]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[mindset]]></category>
		<category><![CDATA[molecule]]></category>
		<category><![CDATA[pathway]]></category>
		<category><![CDATA[predictive]]></category>
		<category><![CDATA[proactive]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reactive]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[sailing]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[value-based]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10126</guid>
		<description><![CDATA[Traditionally, pharmaceutical industry, across the world, is mostly reactive &#8211; rather than proactive or predictive in its strategic approach &#8211; spanning across all its business domains. A large number of pharma players &#8211; both innovators and generic drug makers, formulate &#8230; <a href="http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patient Services Aren’t Optional Any More For Pharma Business Excellence</title>
		<link>http://www.tapanray.in/patient-services-arent-optional-any-more-for-pharma-business-excellence/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patient-services-arent-optional-any-more-for-pharma-business-excellence</link>
		<comments>http://www.tapanray.in/patient-services-arent-optional-any-more-for-pharma-business-excellence/#comments</comments>
		<pubDate>Mon, 20 Mar 2017 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[biotechnology]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[centered]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[conflict]]></category>
		<category><![CDATA[device]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[excellence]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[groups]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[optional]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[Pao]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[providers]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8140</guid>
		<description><![CDATA[In the modern world of abundance of information through various sources and platforms, patients are increasingly looking for greater engagement in their healthcare decision-making process with the doctors, slowly but steadily, and in that process seeking better services from different &#8230; <a href="http://www.tapanray.in/patient-services-arent-optional-any-more-for-pharma-business-excellence/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patient-services-arent-optional-any-more-for-pharma-business-excellence/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Criticizing Pharma Now Just A Fad?</title>
		<link>http://www.tapanray.in/is-criticizing-pharma-now-just-a-fad/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-criticizing-pharma-now-just-a-fad</link>
		<comments>http://www.tapanray.in/is-criticizing-pharma-now-just-a-fad/#comments</comments>
		<pubDate>Sun, 09 Oct 2016 23:46:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ABBvie]]></category>
		<category><![CDATA[Amjevita]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[criticizing]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Fad]]></category>
		<category><![CDATA[Humira]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interchangeable]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7861</guid>
		<description><![CDATA[Is criticizing pharma now just a fad of its stakeholders? Fathoming the right answer to this seemingly simple question may not be too easy, either, for some. The task could even be more onerous, especially when the global ‘researched based’ &#8230; <a href="http://www.tapanray.in/is-criticizing-pharma-now-just-a-fad/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-criticizing-pharma-now-just-a-fad/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Sales Communication: Would ‘Cafeteria Approach’ Be More Productive Today?</title>
		<link>http://www.tapanray.in/pharma-sales-communication-would-cafeteria-approach-be-more-productive-today/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-sales-communication-would-cafeteria-approach-be-more-productive-today</link>
		<comments>http://www.tapanray.in/pharma-sales-communication-would-cafeteria-approach-be-more-productive-today/#comments</comments>
		<pubDate>Mon, 23 Mar 2015 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[applications]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[cafeteria]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[e-marketing]]></category>
		<category><![CDATA[effective]]></category>
		<category><![CDATA[force]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intangible]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[medical representatives]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[practitioners]]></category>
		<category><![CDATA[productive]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[SBU]]></category>
		<category><![CDATA[tangible]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tools]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6465</guid>
		<description><![CDATA[For sales communication, quality of access of pharma Medical Representatives (MRs) to many important and busy doctors has been steadily declining over the past several years, all over the world, and India is no exception. This is mainly because the number of &#8230; <a href="http://www.tapanray.in/pharma-sales-communication-would-cafeteria-approach-be-more-productive-today/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-sales-communication-would-cafeteria-approach-be-more-productive-today/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma FDI: Damning Report of Parliamentary Panel, PM Vetoes&#8230;and Avoids Ruffling Feathers?</title>
		<link>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers</link>
		<comments>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/#comments</comments>
		<pubDate>Mon, 19 Aug 2013 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[acquisitions]]></category>
		<category><![CDATA[addition]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[BRIC]]></category>
		<category><![CDATA[Brownfield]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[Discussion]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[feathers]]></category>
		<category><![CDATA[FIPB]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[illusionary]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[matrix]]></category>
		<category><![CDATA[mergers]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[MNCs]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[oligopolistic]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[PMO]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[protectionism]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[restriction]]></category>
		<category><![CDATA[retrograde]]></category>
		<category><![CDATA[ruffling]]></category>
		<category><![CDATA[Sankyo]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tweaking]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[vetoed]]></category>
		<category><![CDATA[vetoes veto]]></category>
		<category><![CDATA[wrong]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3241</guid>
		<description><![CDATA[An interesting situation emerged last week. The Parliamentary Standing Committee (PSC) on Commerce proposed a blanket ban on all FDI in brownfield pharma sector. Just two days after that, the Prime Minister of India vetoed the joint opposition of the Department &#8230; <a href="http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>To accelerate increasing ‘Access to Modern Medicines’ in India: A Strategic Approach</title>
		<link>http://www.tapanray.in/to-accelerate-increasing-access-to-modern-medicines-in-india-a-strategic-approach/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=to-accelerate-increasing-access-to-modern-medicines-in-india-a-strategic-approach</link>
		<comments>http://www.tapanray.in/to-accelerate-increasing-access-to-modern-medicines-in-india-a-strategic-approach/#comments</comments>
		<pubDate>Mon, 27 Dec 2010 00:30:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accelerate]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[beds]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[Increasing]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Modern]]></category>
		<category><![CDATA[nurses]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=329</guid>
		<description><![CDATA[Currently no one knows what the &#8216;Access to Modern Medicines&#8217; in India is, in real term. Like many others, both local and global. I myself was quoting the World Medicines Situation of 2004 report, the base year of which is actually &#8230; <a href="http://www.tapanray.in/to-accelerate-increasing-access-to-modern-medicines-in-india-a-strategic-approach/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/to-accelerate-increasing-access-to-modern-medicines-in-india-a-strategic-approach/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India urgently needs a total overhaul and reform of its public healthcare system with a holistic approach – NRHM and RSBY are laudable initiatives.</title>
		<link>http://www.tapanray.in/india-urgently-needs-a-total-overhaul-and-reform-of-its-public-healthcare-system-with-a-holistic-approach-nrhm-and-rsby-are-laudable-initiatives/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-urgently-needs-a-total-overhaul-and-reform-of-its-public-healthcare-system-with-a-holistic-approach-nrhm-and-rsby-are-laudable-initiatives</link>
		<comments>http://www.tapanray.in/india-urgently-needs-a-total-overhaul-and-reform-of-its-public-healthcare-system-with-a-holistic-approach-nrhm-and-rsby-are-laudable-initiatives/#comments</comments>
		<pubDate>Mon, 30 Nov 2009 01:30:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[BPL]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[holistic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[initiatives]]></category>
		<category><![CDATA[its]]></category>
		<category><![CDATA[Laudable]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[NRHM]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[overhaul]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[poor]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reform]]></category>
		<category><![CDATA[RSBY]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[total]]></category>
		<category><![CDATA[urgently]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=712</guid>
		<description><![CDATA[Over a period of time India had made significant improvement in various critical health indicators despite frugal public health spending by the government, which is just around 1 percent of GDP of the country. Such a low government spend towards &#8230; <a href="http://www.tapanray.in/india-urgently-needs-a-total-overhaul-and-reform-of-its-public-healthcare-system-with-a-holistic-approach-nrhm-and-rsby-are-laudable-initiatives/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-urgently-needs-a-total-overhaul-and-reform-of-its-public-healthcare-system-with-a-holistic-approach-nrhm-and-rsby-are-laudable-initiatives/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An integrated approach towards Public Private Partnership (PPP) initiatives to improve access to healthcare in India is the way forward.</title>
		<link>http://www.tapanray.in/an-integrated-approach-towards-public-private-partnership-ppp-initiatives-to-improve-access-to-healthcare-in-india-is-the-way-forward/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=an-integrated-approach-towards-public-private-partnership-ppp-initiatives-to-improve-access-to-healthcare-in-india-is-the-way-forward</link>
		<comments>http://www.tapanray.in/an-integrated-approach-towards-public-private-partnership-ppp-initiatives-to-improve-access-to-healthcare-in-india-is-the-way-forward/#comments</comments>
		<pubDate>Wed, 14 Jan 2009 01:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[BPL]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[forward]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[improve]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[initiatives]]></category>
		<category><![CDATA[integrated]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Partnership]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[towards]]></category>
		<category><![CDATA[way]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=974</guid>
		<description><![CDATA[Despite so much of stringent government control, debate and activism on the affordability of modern medicines in India, on the one hand, and the success of the government to make medicines available in the country at a price, which is &#8230; <a href="http://www.tapanray.in/an-integrated-approach-towards-public-private-partnership-ppp-initiatives-to-improve-access-to-healthcare-in-india-is-the-way-forward/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/an-integrated-approach-towards-public-private-partnership-ppp-initiatives-to-improve-access-to-healthcare-in-india-is-the-way-forward/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
